• Pei-Pei Ren, Ming Li, Tian-Fang Li, and Shuang-Yin Han.
• Translational Research Center, People's Hospital of Henan Province, Zhengzhou University, Zhengzhou 450003, China.
• Curr. Pharm. Des. 2017 Jan 1; 23 (14): 2113-2116.

AbstractGlioblastoma (GBM) is one of the most devastating brain tumors with poor prognosis and high mortality. Although radical surgical treatment with subsequent radiation and chemotherapy can improve the survival, the efficacy of such regimens is insufficient because the GBM cells can spread and destroy normal brain structures. Moreover, these non-specific treatments may damage adjacent healthy brain tissue. It is thus imperative to develop novel therapies to precisely target invasive tumor cells without damaging normal tissues. Immunotherapy is a promising approach due to its capability to suppress the growth of various tumors in preclinical model and clinical trials. Adoptive cell therapy (ACT) using T cells engineered with chimeric antigen receptor (CAR) targeting an ideal molecular marker in GBM, e.g. epidermal growth factor receptor type III (EGFRvIII) has demonstrated a satisfactory efficacy in treating malignant brain tumors. Here we summarize the recent progresses in immunotherapeutic strategy using CAR-modified T cells oriented to EGFRvIII against GBM.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

23 keywords...

hide…